The use of biomarkers is becoming increasingly integral to to the contemporary practice of medicine and continues to play a central role in preventive, predictive and personalized medicine. However, the limited number of FDA-approved, in use biomarkers, on one hand, and an increasing number of published potential biomarkers, on the other hand, calls for an accelerated approach to translating biomarker research to clinical application. In this talk, I introduce novel concept of "Biomarker-guided Mechanism Discovery" through an integrative disease modeling approach and present the successful application of this methodology to deciphering the network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect. Moreover, the current challenges in biomarker discovery is discussed and results of our proposed Biomarker Ontology in collaboration with pharma industry will be presented.
How to Cite:
Younesi, E., 2015. Disease systems modeling for discovery of mechanistic biomarkers. European Journal of Molecular & Clinical Medicine, 2(2), p.61. DOI: http://doi.org/10.1016/j.nhtm.2014.11.023
Younesi, E.. “Disease Systems Modeling for Discovery of Mechanistic Biomarkers”. European Journal of Molecular & Clinical Medicine, vol. 2, no. 2, 2015, p. 61. DOI: http://doi.org/10.1016/j.nhtm.2014.11.023